Establishing a risk stratification model to identify clinically high-risk N0 breast cancer who could benefit from regional nodal irradiation: a single institute analysis

被引:0
|
作者
Qi, Wei-Xiang [1 ,2 ]
Cao, Lu [1 ,2 ]
Ou, Dan [1 ,2 ]
Li, Shuyan [1 ,2 ]
Xu, Cheng [1 ,2 ]
Cai, Rong [1 ,2 ]
Xu, Haoping [1 ,2 ]
Cai, Gang [1 ,2 ]
Chen, Jiayi [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Radiat Oncol, Sch Med, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Key Lab Proton Therapy, Sch Med, Shanghai, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金
美国国家科学基金会;
关键词
breast cancer; risk stratification; beast conserving surgery; whole breast irradiation; regional nodal irradiation; INTERNAL MAMMARY; TUMOR LOCATION; FOLLOW-UP; STAGE; MASTECTOMY; RECURRENCE; SURVIVAL; SURGERY; WOMEN;
D O I
10.3389/fonc.2024.1290852
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The purpose of this real-world study was to investigate the risk factors for developing recurrence among patients with pathological T1-3N0 breast cancer (BC) treated with breast-conserving surgery (BCS) followed by whole breast irradiation alone (WBI) and identify those clinically high-risk BCs who could benefit from regional nodal irradiation (RNI). Materials and methods Female BC patients treated at Shanghai Ruijin hospital from 2009 to 2016 were retrospectively reviewed. The disease-free survival (DFS), breast cancer specific survival (BCSS) and overall survival (OS) were estimated by the Kaplan-Meier method, and survival differences were compared with the log-rank test. Univariate and multivariate analysis was performed using Cox proportional hazards regression analysis. An external validation was conducted by using SEER database. Results A total of 622 BC patients treated with BCS+WBI alone were included. With a median follow-up of 82 months, the 7-year OS, BCSS and DFS for the entire cohort was 97%, 99% and 91%, respectively. Multivariable Cox analysis indicated that tumor size (p=0.006), tumor location (p=0.033), lymphovascular invasion (LVI) status (p=0.0028) and Ki-67 index (p=0.051) were independent risk factors for DFS. A scoring system was developed using these four factors and the 7-year DFS and OS were 97% and 96% for patients with 0-1 risk factors, 95% and 82% for patients with >= 2 risk factors (p<0.0001 for DFS, and p=0.0063 for OS). Based on tumor size and tumor location, an external validation by demonstrated that the 7-year OS was 90% and 88% for patients with 0-1 risk factor, which was significantly better than those defined as high-risk BC patients (82%, p<0.0001). Conclusion By using our institute database, we establish a risk stratification system for identifying sub-group of pN0 BC patients, who are at high risk for developing recurrence. The results of our study support tailored RT decision-making according to individual risks, which needed to be confirmed in further studies.
引用
收藏
页数:10
相关论文
共 41 条
  • [31] Benefit of adjuvant chemotherapy in patients with high-risk UICC II colon cancer T4N0M0: A ten-year population based analysis of 3544 cases.
    Teufel, Andreas
    Furst, Alois
    Gerken, Michael
    Hohenthanner, Ina
    Klinkhammer-Schalke, Monika
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [32] Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer
    Teufel, Andreas
    Gerken, Michael
    Fuerst, Alois
    Ebert, Matthias
    Hohenthanner, Ina
    Klinkhammer-Schalke, Monika
    EUROPEAN JOURNAL OF CANCER, 2020, 137 : 148 - 160
  • [33] Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer
    Tramm, Trine
    Kyndi, Marianne
    Myhre, Simen
    Nord, Silje
    Alsner, Jan
    Sorensen, Flemming Brandt
    Sorlie, Therese
    Overgaard, Jens
    ACTA ONCOLOGICA, 2014, 53 (10) : 1337 - 1346
  • [34] Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424)
    Harbeck, N
    Kates, RE
    Look, MP
    Meijer-van Gelder, ME
    Klijn, JGM
    Krüger, A
    Kiechle, M
    Jänicke, F
    Schmitt, M
    Foekens, JA
    CANCER RESEARCH, 2002, 62 (16) : 4617 - 4622
  • [35] Pathological complete response after neoadjuvant chemotherapy in high-risk, early breast cancer patients- a retrospective, single centre analysis from the St. Josef Hospital in Vienna
    Spitaler, A.
    Roider-Schur, S.
    Gartner, V.
    Vormittag, L.
    Kafka, A.
    Weiser-Jasch, O.
    Winkler, T.
    Pfarl, G.
    Sagmeister, T.
    Schmidbauer, U.
    Oehler, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 290 - 290
  • [36] Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
    Nitz, Ulrike
    Gluz, Oleg
    Christgen, Matthias
    Kates, Ronald E.
    Clemens, Michael
    Malter, Wolfram
    Nuding, Benno
    Aktas, Bahriye
    Kuemmel, Sherko
    Reimer, Toralf
    Stefek, Andrea
    Lorenz-Salehi, Fatemeh
    Krabisch, Petra
    Just, Marianne
    Augustin, Doris
    Liedtke, Cornelia
    Chao, Calvin
    Shak, Steven
    Wuerstlein, Rachel
    Kreipe, Hans H.
    Harbeck, Nadia
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 165 (03) : 573 - 583
  • [37] Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
    Ulrike Nitz
    Oleg Gluz
    Matthias Christgen
    Ronald E. Kates
    Michael Clemens
    Wolfram Malter
    Benno Nuding
    Bahriye Aktas
    Sherko Kuemmel
    Toralf Reimer
    Andrea Stefek
    Fatemeh Lorenz-Salehi
    Petra Krabisch
    Marianne Just
    Doris Augustin
    Cornelia Liedtke
    Calvin Chao
    Steven Shak
    Rachel Wuerstlein
    Hans H. Kreipe
    Nadia Harbeck
    Breast Cancer Research and Treatment, 2017, 165 : 573 - 583
  • [38] A BUDGET IMPACT ANALYSIS OF PERTUZUMAB, TRASTUZUMAB, AND CHEMOTHERAPY IN THE NEOADJUVANT SETTING FOR HER2-POSITIVE HIGH-RISK EARLY BREAST CANCER PATIENTS: INSIGHTS FROM THE TUSCANY REGIONAL HEALTH CARE SYSTEM PERSPECTIVE
    Antonazzo, I. C.
    Bengala, C.
    Biganzoli, L.
    Mantovani, L. G.
    Michelotti, A.
    Cortesi, P.
    VALUE IN HEALTH, 2023, 26 (12) : S121 - S121
  • [39] Prognostic analysis of cT1-3N1M0 breast cancer patients who have responded to neoadjuvant therapy undergoing various axillary surgery and breast surgery based on propensity score matching and competitive risk model
    Zhang, Maoquan
    Sun, Yingming
    Wu, Huasheng
    Xiao, Jian
    Chen, Wenxin
    Wang, Hebin
    Yang, Binglin
    Luo, Huatian
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [40] Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
    Ulrike Nitz
    Oleg Gluz
    Matthias Christgen
    Ronald E. Kates
    Michael Clemens
    Wolfram Malter
    Benno Nuding
    Bahriye Aktas
    Sherko Kuemmel
    Toralf Reimer
    Andrea Stefek
    Fatemeh Lorenz-Salehi
    Petra Krabisch
    Marianne Just
    Doris Augustin
    Cornelia Liedtke
    Calvin Chao
    Steven Shak
    Rachel Wuerstlein
    Hans H. Kreipe
    Nadia Harbeck
    Breast Cancer Research and Treatment, 2019, 175 : 265 - 266